June 24, 2017 5:12 PM ET

Life Sciences Tools and Services

Company Overview of Samsung Biologics Co., Ltd.

Company Overview

Samsung BioLogics Co., Ltd. engages in the research, development, and commercialization of biopharmaceutical products worldwide. The company develops immunosuppressant biosimilars, such as Enbrel under the Brenzys and Benepali brand names; and Remicade under the Renflexis and Flixabi brands. Its products also include antidiabetic agents, other biosimilars of immunosuppressant drugs, and breasts cancer drugs, which are under regulatory’s deliberation stage. In addition, the company offers process development services, including upstream, downstream, and analytical technology; cell culture and purification; fill and finish, lyophilization, and support processes; quality and compliance, and qua...

300, Songdo Bio-daero

Yeonsu-gu

Incheon,  21987

South Korea

Founded in 2011

Key Executives for Samsung Biologics Co., Ltd.

Samsung Biologics Co., Ltd. does not have any Key Executives recorded.

Samsung Biologics Co., Ltd. Key Developments

Samsung BioLogics Co., Ltd. Announces Earnings Results for the First Quarter of 2017

Samsung BioLogics Co., Ltd. announced earnings results for the first quarter of 2017. The company posted quarterly sales of KRW 107.6 billion and quarterly operating profits of KRW 3.4 billion. Sales increased KRW 2.1 billion (1.9%) as its product shipments increased. Also as sales increased and SG&A (Selling, General and Administrative Expenses) decreased, operating profits increased KRW 4.1 billion to turn profitable. It also posted net loss of KRW 33.1 billion, reflecting the equity method of biosimilar development and clinical expenses for the company's subsidiary, including Samsung Bioepis and Archigen Biotech.

Samsung Biologics Co., Ltd. to Report Q1, 2017 Results on Apr 25, 2017

Samsung Biologics Co., Ltd. announced that they will report Q1, 2017 results on Apr 25, 2017

Samsung Biologics Co., Ltd. Presents at Korea Investor Conference, Mar-09-2017

Samsung Biologics Co., Ltd. Presents at Korea Investor Conference, Mar-09-2017 . Venue: Conrad Hotel, 23-1 Yeouido-dong Yeongdeungpo-gu, Seoul, 150-945, South Korea.

Similar Private Companies By Industry

Company Name Region
AbClon Inc. Asia
ADM Korea Inc. Asia
Aedeub Baenseu Development Co., Ltd. Asia
B&C Biopharm Co. Ltd. Asia
Bio-Medieng Co. Ltd. Asia

Recent Private Companies Transactions

Type
Date
Target
Private Placement
November 22, 2016
Samsung Bioepis Co., Ltd.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Samsung Biologics Co., Ltd., please visit www.samsungbiologics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.